Currently, single or combined therapies of MAPK inhibitors Trametinib, Abrafenib, and Vemurafenib have been used in BRAF V600-mutated melanoma 56-58, BRAF-mutated non-small cell lung cancer 59,60 and anaplastic thyroid cancer 61. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.